[Clinical significance of comprehensive genomic profiling in hematopoietic failure]

Area of Science:

• Hematology
• Genomics
• Precision Medicine

Background:

• Comprehensive genomic profiling (CGP) is increasingly vital in diagnosing and managing hematologic disorders.
• Japanese National Health Insurance now covers CGP for hematologic malignancies, promoting genome-based precision medicine.
• Conventional methods like morphology and cytogenetics are complemented by genomic insights.

Purpose of the Study:

• To review the clinical significance of CGP in patients with hematopoietic failure.
• To guide the interpretation of CGP results for optimizing clinical management.
• To highlight CGP's role in differentiating bone marrow failure phenotypes and evaluating genetic alterations.

Main Methods:

• Review of clinical significance and applications of CGP in hematopoietic failure.
• Analysis of CGP's utility in differentiating aplastic anemia from myelodysplastic syndromes.
• Discussion of CGP's contribution to prognostic stratification and inherited bone marrow failure syndromes.

Main Results:

• CGP aids in differentiating aplastic anemia from myelodysplastic syndromes and related diseases.
• CGP assists in prognostic stratification and evaluating inherited bone marrow failure syndromes.
• Accurate CGP interpretation requires understanding genetic pathology, CGP characteristics, and potential pitfalls.

Conclusions:

• CGP is a valuable tool for diagnosing and managing hematopoietic failure, offering a precision medicine approach.
• Understanding CGP's nuances, including pitfalls like clonal hematopoiesis, is crucial for effective clinical application.
• This review aims to enhance the interpretation of CGP results for improved patient outcomes in hematopoietic failure.